The Management of Head and Neck Cancers
The medical approach and technical delivery of radiotherapy for cancers of the head and neck is multidisciplinary in nature, and technically complex. This session will cover current best practices/clinical guidelines with respect to multidisciplinary treatment options and treatment approaches for head and neck cancer. Topics covered will include definitive versus postoperative radiotherapy, as well as the indications for using chemotherapy/targeted agents in conjunction with radiotherapy. Other topics that will be covered include best practices/approaches to radiation treatment delivery, including target delineation, RT dose and normal tissue constraints. Finally, time will be spent discussing how recent clinical results and publications for specific subtypes of head and neck cancer (HPV-positive oropharynx cancer) may affect current and future approaches to this disease, particularly in toxicity mitigation and treatment de-intensification.
This program is designed to meet the interest of radiation oncologists, nurses, radiation therapists, dosimetrists and radiation oncology residents.
- Predict disease outcomes and survival for the major categories/subsites of head and neck cancer.
- Determine the best clinical and technical approaches for definitive and postoperative head and neck cancer radiotherapy treatment.
- Apply recent published findings concerning HPV status to the management of oropharyngeal and non-oropharyngeal cancers.
Alexander Lin, MD, is employed at the University of Pennsylvania and receives compensation from Elekta.
The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.
ASTRO members must log in to the ASTRO website to view and receive the discounted member rate.
- Nonmember: $105
- Member: $55
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the course by the end of the qualification date. The qualification date for each course is listed in the course catalog on the ASTRO website under availability.
Participants using ASTRO's online courses to satisfy the requirement of a Maintenance of Certification (MOC) program should verify the number, type and availability dates of any course before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased courses that do not align with their MOC requirement.
The course and its materials will only be available on the ASTRO website for that 3 year period regardless of purchase date. At the expiration of the qualification, participants will no longer have access to the course or its materials. ASTRO reserves the right to remove a course before the end of its qualification period.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.